Autoimmune Hepatitis

Autoimmune Hepatitis — scientific infographic poster

Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease caused by the immune system attacking the body's own hepatocytes. It affects predominantly women (70%; the 2025 British Society of Gastroenterology (BSG) guideline gives about 3 women to 1 man in the UK) and follows a bimodal age distribution — a first peak in adolescence and young adulthood, and a second peak around perimenopause. AIH can masquerade as virtually every other liver disease: it may present as acute hepatitis indistinguishable from viral infection, as chronic hepatitis discovered incidentally on blood tests, or as cirrhosis presenting with its complications. The treacherous part is that without treatment, AIH progresses silently to cirrhosis in the majority of patients — yet with the right treatment, most patients achieve complete remission and a normal life expectancy.

  1. Overview
  2. Type 1 vs Type 2 AIH
  3. Pathophysiology
  4. Clinical Presentation
  5. Diagnosis and the Simplified IAIHG Criteria
  6. Liver Biopsy and Histology
  7. Treatment
  8. Overlap Syndromes: AIH-PSC and AIH-PBC
  9. Pregnancy With Autoimmune Hepatitis
  10. Key Research Papers
  11. Connections

Overview

Autoimmune hepatitis is defined by three features: (1) elevated serum transaminases (aspartate aminotransferase (AST)/alanine aminotransferase (ALT)), typically 5–50 times the upper limit of normal; (2) characteristic autoantibodies (antinuclear antibody (ANA), anti-smooth muscle antibody (ASMA), anti-liver-kidney microsomal antibody type 1 (anti-LKM1)); and (3) interface hepatitis on liver biopsy — a histological pattern of lymphocytic and plasma cell infiltration eroding the boundary between the portal tract and the liver parenchyma (the "limiting plate"). A fourth feature, elevated immunoglobulin G (IgG), is present in 85% of patients and is an important diagnostic clue.

AIH is rare — prevalence approximately 10–20 per 100,000 in European and North American populations — but its importance lies in its treatability. A 2023 meta-analysis of 37 studies gives a global prevalence of 15.65 per 100,000, rising from 9.95 per 100,000 in 1970–1999 to 27.91 per 100,000 in 2015–2022, with about 1.28 new cases per 100,000 people per year. Untreated, approximately 40% of patients with severe AIH die within 6 months. With standard immunosuppressive treatment, 80–90% achieve biochemical remission and 5-year survival exceeds 90%. This dramatic treatment benefit makes early recognition critical.

Key clinical associations:

Back to Table of Contents

Type 1 vs Type 2 AIH

AIH is divided into two subtypes based on autoantibody profile:

Type 1 AIH (most common, ~80% of AIH)

Autoantibody markers:

Type 2 AIH (less common, ~20%, predominantly children and adolescents)

Autoantibody markers:

Practical note: Type 1 and Type 2 are not distinguished by treatment — both receive the same prednisolone ± azathioprine protocol. The distinction matters for diagnostic workup and for understanding disease behavior.

Back to Table of Contents

Pathophysiology

AIH results from breakdown of immune tolerance to hepatocyte antigens, with proposed roles for both regulatory T cells (Tregs; disputed, see below) and aberrant effector immune responses.

Molecular Mimicry Hypothesis

Environmental triggers (viruses, drugs, environmental antigens) present peptide sequences that share structural similarity with hepatocyte proteins. Cytochrome P450 2D6 in Type 2 AIH is a clear example: a peptide from the hepatitis C virus (HCV) mimics the cytochrome P450 2D6 epitope targeted by anti-LKM1, potentially explaining how hepatitis C virus infection can trigger Type 2 AIH. Measles virus and herpes simplex virus have also been proposed as molecular mimics for other AIH autoantigens.

Defective Regulatory T Cell (Treg) Suppression

Tregs normally suppress autoreactive effector T cells. Whether they are defective in AIH is disputed. Earlier studies described Tregs as quantitatively reduced in peripheral blood and liver, and functionally impaired — failing to suppress CD4+ and CD8+ T cells that recognize hepatocyte antigens. A 2012 study by Peiseler and colleagues, using staining that separates Tregs from activated T cells, reported that "the frequency and function of circulating Treg cells is not impaired in AIH"; it noted that the earlier studies "had used only CD25" as a marker, and found Treg frequency in the liver higher than in fatty-liver inflammation (non-alcoholic steatohepatitis), rising with inflammation. A 2023 meta-analysis of 29 studies found Treg proportions in blood generally decreased, with results depending on the markers used, ethnicity and disease activity. A 2026 study of 57 patients found more Tregs in the liver but markedly reduced suppressive capacity in the laboratory. It has also been proposed that mutations in FoxP3 (the master transcription factor of Tregs) and IL-2 signaling pathways (shared with Type 1 diabetes) account for part of any defect; this is not established.

Th1/Th17 Effector Response

Autoreactive CD4+ T helper cells in AIH are skewed toward Th1 (producing IFN-γ and tumor necrosis factor alpha (TNF-α)) and Th17 (producing IL-17) phenotypes. These cytokines activate:

Plasma Cell Infiltration

A distinctive feature of AIH histology is hepatic plasma cell infiltration. Activated B cells mature into plasma cells within the liver, producing local immunoglobulin G that is reflected in the elevated serum immunoglobulin G. This polyclonal immunoglobulin G elevation (immunoglobulin G typically 1.5–3× upper limit of normal in active AIH) is a key diagnostic feature and a biomarker of treatment response (immunoglobulin G normalizes with effective immunosuppression).

Genetic Architecture

HLA-DR3 and HLA-DR4 present autoantigenic peptides on CD4+ T cells in the context of hepatic injury. HLA-DR3 (DRB1*0301) is associated with more severe disease, younger onset, and higher relapse rates; HLA-DR4 (DRB1*0401) is associated with milder disease, older onset, and better response to azathioprine. Non-HLA loci include PTPN22 (lymphocyte phosphatase, shared with rheumatoid arthritis (RA) and type 1 diabetes) and SH2B3.

Back to Table of Contents

Clinical Presentation

AIH has three main presentations:

1. Acute Hepatitis Presentation (30–40% of Cases)

2. Chronic Asymptomatic Presentation (30–50% of Cases)

3. Presentation with Established Cirrhosis

Physical Examination

Laboratory Pattern

Back to Table of Contents

Diagnosis and the Simplified IAIHG Criteria

AIH diagnosis requires integrating clinical, serological, and histological data. The International Autoimmune Hepatitis Group (IAIHG) has published two scoring systems: the original complex scoring system and the simplified 2008 criteria.

IAIHG Simplified Criteria (2008)

Variable Finding Points
Antinuclear antibody or ASMA ≥1:40 +1
Antinuclear antibody or ASMA ≥1:80 +2
Anti-LKM1 ≥1:40 +2
Anti-SLA/LP Positive +2
Immunoglobulin G >upper limit of normal +1
Immunoglobulin G >1.10 × upper limit of normal +2
Liver histology Compatible with AIH +1
Liver histology Typical of AIH +2
Absence of viral hepatitis Yes +2

Score Interpretation

Practical Workup Sequence

  1. Viral hepatitis excluded: hepatitis A virus immunoglobulin M (IgM), hepatitis B surface antigen (HBsAg), hepatitis B core antibody IgM, hepatitis C virus antibody (with reflex RNA if positive), hepatitis E virus (HEV) IgM
  2. Autoantibodies measured: antinuclear antibody (immunofluorescence on Hep-2 cells), ASMA (immunofluorescence), anti-LKM1 (immunofluorescence), anti-SLA/LP (enzyme-linked immunosorbent assay, ELISA)
  3. Immunoglobulin G measured (and immunoglobulin A (IgA), immunoglobulin M to assess pattern)
  4. Liver biopsy (virtually always required for definitive diagnosis and fibrosis staging)
  5. Abdominal ultrasound (baseline; assess liver echogenicity, portal flow)
  6. If cholestatic features (elevated alkaline phosphatase/GGT): magnetic resonance cholangiopancreatography (MRCP) to evaluate for overlap with primary sclerosing cholangitis

Drug-Induced AIH

Many drugs cause AIH-like reactions with identical serological and histological findings: minocycline, nitrofurantoin, statins, methyldopa (alpha-methyldopa), hydralazine, isoniazid. Drug-induced AIH may resolve with drug withdrawal alone. A detailed drug history is part of the workup, including herbal supplements: kava, comfrey and germander have caused AIH-like drug reactions.

Back to Table of Contents

Liver Biopsy and Histology

Liver biopsy is essential in AIH for three reasons: (1) to confirm the diagnosis, (2) to stage fibrosis, and (3) to establish a histological baseline for monitoring treatment response.

Characteristic Histological Features

Interface Hepatitis (the Cardinal Lesion)

Lymphocytes and plasma cells spill from portal tracts across the limiting plate into the periportal hepatocyte parenchyma, destroying periportal hepatocytes in clusters. This periportal hepatitis eroding the limiting plate is the defining histological feature and is responsible for the "rosette" formation described below.

Plasma Cell Infiltrate

Dense plasma cell infiltration — often described as the "most striking" feature by experienced pathologists — is highly characteristic of AIH. Plasma cells are rare or absent in viral hepatitis and metabolic dysfunction-associated steatotic liver disease (MASLD), making their presence a strong diagnostic pointer. In acute severe AIH, plasma cells may be sparse ("plasma-cell-poor AIH"), which can mislead the pathologist.

Hepatocyte Rosette Formation

Remaining periportal hepatocytes, hemmed in by the inflammatory infiltrate, arrange themselves in a gland-like ring (rosette) around a dilated bile canaliculus or central hepatocyte. Rosettes are not specific to AIH but are characteristic.

Emperipolesis

Lymphocytes penetrating into hepatocyte cytoplasm (lymphocyte emperipolesis) — a more specific feature of AIH when prominent; distinct from hepatocyte apoptosis which produces Councilman bodies.

Fibrosis Staging

Staged F0–F4 by the Metavir or Ishak system. Approximately 30% of newly-diagnosed AIH patients already have F3–F4 fibrosis at first biopsy, emphasizing the silent progression of untreated disease.

Back to Table of Contents

Treatment

AIH treatment has two phases: induction of remission and long-term maintenance.

Indications for Treatment

Standard Induction — Regimens in Liver-Society Guidance

Option 1 (preferred for women, young patients, type 2 diabetes risk):

Option 2 (monotherapy with prednisolone alone):

Budesonide (for Non-Cirrhotic AIH)

Monitoring Remission

Treatment Withdrawal

Second-Line Therapies (azathioprine Intolerance, Refractory Disease)

Newer Trials and Guidelines

Liver Transplantation

Back to Table of Contents

Overlap Syndromes: AIH-PSC and AIH-PBC

AIH overlaps with the two other autoimmune liver diseases, primary sclerosing cholangitis and primary biliary cholangitis, in approximately 7–10% of cases. These overlap syndromes require modified treatment.

AIH-PSC Overlap

AIH-PBC Overlap (Paris Criteria Diagnosis)

Paris Criteria require at least 2 of 3 features from each disease:

The 2025 BSG guideline recommends that the revised and simplified IAIHG scores not be used to diagnose these variant syndromes, and states that the Paris criteria can be used "but do not identify all patients".

Back to Table of Contents

Pregnancy With Autoimmune Hepatitis

In a two-center study of 197 pregnancies in 112 women with autoimmune hepatitis, 88% ended in a live birth and 24% in preterm delivery. Preterm birth was more common with cirrhosis (33% vs 16%), although live birth rates were similar. Loss of disease control on blood tests was more common after delivery than during pregnancy (25% vs 6%). Intrahepatic cholestasis of pregnancy occurred in 9% and preeclampsia in 8%.

The 2025 BSG guideline states that azathioprine, tacrolimus, prednisolone and budesonide "appear safe in pregnancy and also, during breastfeeding", and recommends continuing corticosteroids with or without thiopurines throughout pregnancy. Mycophenolate mofetil is the exception: it causes birth defects (see Second-Line Therapies above).

Back to Table of Contents

Key Research Papers

  1. Manns MP et al. "Diagnosis and Management of Autoimmune Hepatitis." Hepatology 2010 (AASLD practice guidelines) — PubMed PMID: 20513004
  2. Hennes EM et al. "Simplified criteria for the diagnosis of autoimmune hepatitis." Hepatology 2008 (simplified IAIHG scoring) — PubMed PMID: 18537184
  3. European Association for the Study of the Liver. "EASL Clinical Practice Guidelines: Autoimmune hepatitis." Journal of Hepatology 2015. — PubMed PMID: 26341719
  4. Johnson PJ, McFarlane IG. "Meeting report: International Autoimmune Hepatitis Group." Hepatology 1993 (original IAIHG scoring system) — PubMed PMID: 8406375
  5. Vergani D et al. "Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group." Journal of Hepatology 2004. — PubMed PMID: 15464251
  6. Lohse AW, Mieli-Vergani G. "Autoimmune hepatitis." Journal of Hepatology 2011. — PubMed PMID: 21167232
  7. Czaja AJ. "Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions." Gut and Liver 2016. — PubMed PMID: 26934884
  8. Heneghan MA et al. "Autoimmune hepatitis." Lancet 2013. — PubMed PMID: 23768844
  9. Gregorio GV et al. "Autoimmune hepatitis in childhood: a 20-year experience." Hepatology 1997 (Type 2 AIH in children) — PubMed PMID: 9049195
  10. Chazouillères O et al. "Primary biliary cirrhosis–autoimmune hepatitis overlap syndrome: clinical features and response to therapy." Hepatology 1998 (Paris criteria AIH-PBC) — PubMed PMID: 9695990
  11. Zachou K et al. "Review article: autoimmune hepatitis -- current management and challenges." Alimentary Pharmacology & Therapeutics 2013. — PubMed PMID: 24010812
  12. Mack CL et al. "Diagnosis and Management of Autoimmune Hepatitis in Adults and Children." Hepatology 2020. — PubMed PMID: 31863477
  13. Gleeson D et al. "British Society of Gastroenterology guidelines for diagnosis and management of autoimmune hepatitis." Gut 2025. — PubMed PMID: 40169244
  14. European Association for the Study of the Liver. "EASL Clinical Practice Guidelines on the management of autoimmune hepatitis." Journal of Hepatology 2025. — PubMed PMID: 40348684
  15. Snijders RJALM et al. "An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis." Journal of Hepatology 2024. — PubMed PMID: 38101756
  16. Slooter CD et al. "Azathioprine versus mycophenolate mofetil in treatment-naive autoimmune hepatitis: 3-year follow-up of the CAMARO-trial." JHEP Reports 2026. — PubMed PMID: 42880409
  17. Lammert CS et al. "Safety and efficacy of zetomipzomib in relapsed or insufficiently responding autoimmune hepatitis: Results from the randomized, double-blind, placebo-controlled, phase 2a PORTOLA study and open-label extension." Hepatology 2026. — PubMed PMID: 42770396
  18. Chung Y et al. "Pregnancy outcomes in an international cohort of autoimmune hepatitis." JHEP Reports 2026. — PubMed PMID: 42217578
  19. Hahn JW et al. "Global incidence and prevalence of autoimmune hepatitis, 1970-2022: a systematic review and meta-analysis." EClinicalMedicine 2023. — PubMed PMID: 37876996
  20. Peiseler M et al. "FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency." Journal of Hepatology 2012. — PubMed PMID: 22425700
  21. Huang Z et al. "The proportion of regulatory T cells in peripheral blood of patients with autoimmune hepatitis: A systematic review and meta-analysis." International Immunopharmacology 2023. — PubMed PMID: 37390643
  22. Kwon MH et al. "Expanded but dysfunctional regulatory T cells in treatment-naive autoimmune hepatitis." Hepatology International 2026. — PubMed PMID: 41364306

Back to Table of Contents

Connections

Back to Table of Contents